The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
John B. Sunwoo
Thyroid and parathyroid surgeon, Cutaneous oncology specialist, Head and neck surgical oncologist, Head and neck surgeon, Endocrine surgeon, Surgical oncologist, Dermato-oncology specialist
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Bio:
Dr. Sunwoo was born and raised in St. Louis, Missouri. He received his undergraduate degree from Brown University in Providence, Rhode Island and his medical degree from Washington University in St. Louis, Missouri. He completed his training in Otolaryngology – Head and Neck Surgery at Washington University. Dr. Sunwoo has been at Stanford University since 2008, and his clinical focus is on the surgical management of head and neck cancer, specifically focusing on melanoma and neoplasms of the thyroid and parathyroid glands. He is a member of the Pigmented Lesions and Melanoma Clinic and the Melanoma Working Group at Stanford. He is also the co-founder of the Stanford Thyroid and Parathyroid Tumor Board.
In addition to his clinical work, Dr. Sunwoo is the Director of Head and Neck Cancer Research at Stanford University and the principal investigator of an NIH-funded laboratory in the Stanford Cancer Institute. His research is focused on three primary areas: (1) the immune response to cancer, particularly a tumorigenic population of cells within malignancies called cancer stem cells; (2) the biology and developmental programs of a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity in head and neck cancer.
In addition to his clinical work, Dr. Sunwoo is the Director of Head and Neck Cancer Research at Stanford University and the principal investigator of an NIH-funded laboratory in the Stanford Cancer Institute. His research is focused on three primary areas: (1) the immune response to cancer, particularly a tumorigenic population of cells within malignancies called cancer stem cells; (2) the biology and developmental programs of a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity in head and neck cancer.
- 900 Blake Wilbur Drive
- 3rd Floor
- Palo Alto , CA 94304
- Phone: 650-498-6000
- 900 Blake Wilbur Drive
- 3rd Floor
- Palo Alto , CA 94304
- Phone: 650-498-6000
- 900 Blake Wilbur Drive
- 3rd Floor
- Palo Alto , CA 94304
- Phone: 650-498-6000
- 900 Blake Wilbur Drive
- 3rd Floor
- Palo Alto , CA 94304
- Phone: 650-498-6000
Practice Areas
Professional Education
- Residency: Washington University School Of Medicine Registrar (2003) MO
- Medical Education: Washington University School Of Medicine Registrar (1993) MO
- Postdoc Research Fellowship, Washington University, Immunology (2008)
- Board Certification: Otolaryngology, American Board of Otolaryngology (2004)
- Fellowship: National Institutes of Health (2000) MD
- M.D., Washington University, Medicine (1993)
- Sc.B., Brown University, Biochemistry (1989)
Honors & Awards
- Alpha Omega Alpha, Washington University (2003)
- Best Doctors in America, Best Doctors, Inc. (2009-present)
- Chief Resident Teaching Award, Washington University (2003)
- Faculty Teacher of the Year, Dept. of Otolaryngology, Stanford University (2012)
- K08 Award, National Institutes of Health (2004)
- Louis and Dorothy Kovitz Prize in Surgery, Washington University (1993)
- Resident Research Award, Washington University (1997, 1999, 2000)
- Sigma Xi, Brown University (1989)
- Top Doctors, Castle Connolly (2013 - present)
- Young Investigator Award, American Head and Neck Society (2000)
Administrative Appointments
- Associate Dean for Academic Affairs (UTL), Stanford University School of Medicine (2019 - Present)
- Director of Head and Neck Cancer Research, Stanford University School of Medicine, Dept. of Otolaryngology (2013 - Present)
- Leader, Head and Neck Cancer Service Line (CCP), Stanford Cancer Institute (2017 - Present)
Publications
-
Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p
Sunwoo, J. B., Sun, P. C., Gupta, V. K., Schmidt, A. P., El-Mofty, S., & Scholnick, S. B. (1999). Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. ONCOGENE, 18(16), 2651–2655. -
Multiple regions of deletion on chromosome arm 13q in head-and-neck squamous-cell carcinoma
Gupta, V. K., Schmidt, A. P., Pashia, M. E., Sunwoo, J. B., & Scholnick, S. B. (1999). Multiple regions of deletion on chromosome arm 13q in head-and-neck squamous-cell carcinoma. INTERNATIONAL JOURNAL OF CANCER, 84(5), 453–457. -
Constitutive activation of transcription factors NF-kappa B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines
Ondrey, F. G., Dong, G., Sunwoo, J., Chen, Z., Wolf, J. S., Crowl-Bancroft, C. V., … Van Waes, C. (1999). Constitutive activation of transcription factors NF-kappa B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. MOLECULAR CARCINOGENESIS, 26(2), 119–129. -
Homozygous deletions define a region of 8p23.2 containing a putative tumor suppressor gene
Sun, P. C., Schmidt, A. P., Pashia, M. E., Sunwoo, J. B., & Scholnick, S. B. (1999). Homozygous deletions define a region of 8p23.2 containing a putative tumor suppressor gene. GENOMICS, 62(2), 184–188.
-
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer
Sunwoo, J. B., Herscher, L. L., Kroog, G. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., … Van Waes, C. (2001). Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. JOURNAL OF CLINICAL ONCOLOGY, 19(3), 800–811.
-
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappa B signal pathways
Bancroft, C. C., Chen, Z., Dong, G., Sunwoo, J. B., Yeh, N., PARK, C., & Van Waes, C. (2001). Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappa B signal pathways. CLINICAL CANCER RESEARCH, 7(2), 435–442.
-
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Bancroft, C. G., Sausville, E., … Van Waes, C. (2001). Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. CLINICAL CANCER RESEARCH, 7(5), 1419–1428.
-
IL (interleukin)-1 alpha promotes nuclear factor-kappa B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas
Wolf, J. S., Chen, Z., Dong, G., Sunwoo, J. B., Bancroft, C. C., Capo, D. E., … Van Waes, C. (2001). IL (interleukin)-1 alpha promotes nuclear factor-kappa B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. CLINICAL CANCER RESEARCH, 7(6), 1812–1820.
-
Transcript map of the 8p23 putative tumor suppressor region
Sun, P. C., Uppaluri, R., Schmidt, A. P., Pashia, M. E., Quant, E. C., Sunwoo, J. B., … Scholnick, S. B. (2001). Transcript map of the 8p23 putative tumor suppressor region. GENOMICS, 75(1-3), 17–25.
-
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappa B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines
Bancroft, C. C., Chen, Z., Yeh, J., Sunwoo, J. B., Yeh, N. T., Jackson, S., … Van Waes, C. (2002). Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappa B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. INTERNATIONAL JOURNAL OF CANCER, 99(4), 538–548.
-
Nuclear factor-kappa B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
Loercher, A., Lee, T. L., Ricker, J. L., Howard, A., Geoghegen, J., Chen, Z., … Van Waes, C. (2004). Nuclear factor-kappa B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. CANCER RESEARCH, 64(18), 6511–6523.
-
Inhibition of nuclear factor-kappa B and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
Van Waes, C., Chang, A. A., Lebowitz, P. F., Druzgal, C. H., Chen, Z., Elsayed, Y. A., … Conley, B. A. (2005). Inhibition of nuclear factor-kappa B and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(5), 1400–1412.
-
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y. J., Yang, L. P., … Yokoyama, W. M. (2005). Licensing of natural killer cells by host major histocompatibility complex class I molecules. NATURE, 436(7051), 709–713.
-
Arrested natural killer cell development associated with transgene insertion into the Atf2 locus
Kim, S., Song, Y. J., Higuchi, D. A., Kang, H. P., Pratt, J. R., Yang, L. P., … Yokoyama, W. M. (2006). Arrested natural killer cell development associated with transgene insertion into the Atf2 locus. BLOOD, 107(3), 1024–1030.
-
Mycotic pseudoaneurysm of the internal maxillary artery - Case report and review of the literature
Dunn, G. P., Uppaluri, R., Hessler, J. L., Layland, M. K., Derdeyn, C. P., & Sunwoo, J. B. (2007). Mycotic pseudoaneurysm of the internal maxillary artery - Case report and review of the literature. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 133(4), 402–406.
-
Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia
Dunn, G. P., Lewis, J. S., Sunwoo, J. B., & Uppaluri, R. (2008). Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 30(2), 267–272.
-
Temporal Relationship Between Antitumor Necrosis Factor-alpha Antibody Therapy and Recrudescence of Head and Neck Squamous Cell Carcinoma
Engel, S. H., Hullar, T. E., Adkins, D. R., Thorstad, W. L., & Sunwoo, J. B. (2008). Temporal Relationship Between Antitumor Necrosis Factor-alpha Antibody Therapy and Recrudescence of Head and Neck Squamous Cell Carcinoma. LARYNGOSCOPE, 118(3), 450–452.
-
HLA alleles determine differences in human natural killer cell responsiveness and potency
Kim, S., Sunwoo, J. B., Yang, L., Choi, T., Song, Y.-J., French, A. R., … Yokoyama, W. M. (2008). HLA alleles determine differences in human natural killer cell responsiveness and potency. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(8), 3053–3058.
-
Distal-less homeobox transcription factors regulate development and maturation of natural killer cells
Sunwoo, J. B., Kim, S., Yang, L., Naik, T., Higuchi, D. A., Rubenstein, J. L., & Yokoyama, W. M. (2008). Distal-less homeobox transcription factors regulate development and maturation of natural killer cells. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(31), 10877–10882.
-
A cisplatin-resistant subpopulation of mesenchymal-like cells in head and neck squamous cell carcinoma
Sunwoo, J. B. (2011). A cisplatin-resistant subpopulation of mesenchymal-like cells in head and neck squamous cell carcinoma. CELL CYCLE, 10(17), 2834–35.
-
-
-
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., … Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6662–67.
-
The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles
Jang, E.-S., Shin, J.-H., Ren, G., Park, M.-J., Cheng, K., Chen, X., … Cheng, Z. (2012). The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles. BIOMATERIALS, 33(22), 5584–92.
-
-
Identification of human NK cells that are deficient for signaling adaptor FcR gamma and specialized for antibody-dependent immune functions
Hwang, I., Zhang, T., Scott, J. M., Kim, A. R., Lee, T., Kakarla, T., … Kim, S. (2012). Identification of human NK cells that are deficient for signaling adaptor FcR gamma and specialized for antibody-dependent immune functions. INTERNATIONAL IMMUNOLOGY, 24(12), 793–802.
-
-
Epigenetically mediated pathogenic effects of phenanthrene on regulatory T cells.
Liu, J., Zhang, L., Winterroth, L. C., Garcia, M., Weiman, S., Wong, J. W., … Nadeau, K. C. (2013). Epigenetically mediated pathogenic effects of phenanthrene on regulatory T cells. Journal of Toxicology, 2013, 967029-?
-
CELL-CYCLE OSCILLATION OF PHOSPHATASE INHIBITOR-2 IN RAT FIBROBLASTS COINCIDENT WITH P34CDC2 RESTRICTION
Brautigan, D. L., Sunwoo, J., Labbe, J. C., Fernandez, A., & Lamb, N. J. C. (1990). CELL-CYCLE OSCILLATION OF PHOSPHATASE INHIBITOR-2 IN RAT FIBROBLASTS COINCIDENT WITH P34CDC2 RESTRICTION. NATURE, 344(6261), 74–78.
-
Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer
Sunwoo, J. B., Holt, M. S., Radford, D. M., Deeker, C., & Scholnick, S. B. (1996). Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. GENES CHROMOSOMES & CANCER, 16(3), 164–169.
-
Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx
Scholnick, S. B., Haughey, B. H., Sunwoo, J. B., ELMOFTY, S. K., Baty, J. D., Piccirillo, J. F., & Zequeira, M. R. (1996). Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 88(22), 1676–1682.
-
Clinical correlations with allelotype in supraglottic squamous cancer
Scholnick, S. B., El-Mofty, S. K., Shaw, M. E., Sunwoo, J. B., Haughey, B. H., Sun, P. C., … Zequeira, M. R. (1998). Clinical correlations with allelotype in supraglottic squamous cancer. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 118(3), 363–370.
-
Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., … Levy, R. (2012). Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
-
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
Shin, J. H., Zhang, L., Murillo-Sauca, O., Kim, J., Kohrt, H. E. K., Bui, J. D., & Sunwoo, J. B. (2013). Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(30), 12391–96.
-
-
Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Protein Induction of Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells
Wang, L., Tian, W.-D., Xu, X., Nie, B., Lu, J., Liu, X., … Li, X.-P. (2014). Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Protein Induction of Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells. CANCER, 120(3), 363–72.
-
-
-
-
CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.
Allen, C. T., Conley, B., Sunwoo, J. B., & Van Waes, C. (2015). CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer. Clinical Cancer Research , 21(5), 942–43.
-
Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men
Kaveh, A. H., Seminara, N. M., Barnes, M. A., Berger, A. J., Chen, F. W., Yao, M., … Sunwoo, J. B. (2016). Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38, E754–E760.
-
Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.
Farnebo, L., Shahangian, A., Lee, Y., Shin, J. H., Scheeren, F. A., & Sunwoo, J. B. (2015). Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget, 6(12), 9897–9907.
-
Ameloblastoma: a clinical review and trends in management
McClary, A. C., West, R. B., McClary, A. C., Pollack, J. R., Fischbein, N. J., Holsinger, C. F., … Sirjani, D. (2016). Ameloblastoma: a clinical review and trends in management. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273(7), 1649–61.
-
Tumor Ulceration Does Not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults.
Keegan, T. H. M., Swetter, S. M., Tao, L., Sunwoo, J. B., & Clarke, C. A. (2015). Tumor Ulceration Does Not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults. Journal of Investigative Dermatology, 135(12), 3195–97.
-
ß-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging.
King, M. T., Carpenter, C. M., Sun, C., Ma, X., Le, Q.-T., Sunwoo, J. B., … Xing, L. (2015). ß-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 56(9), 1458–64.
-
A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers.
Pollom, E. L., Wang, E., Bui, T. T., Ognibene, G., von Eyben, R., Divi, V., … Hara, W. Y. (2015). A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. Oral Oncology, 51(12), 1132–37.
-
Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Schoppy, D. W., & Sunwoo, J. B. (2015). Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 29(6), 1033–43.
-
-
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.
Brooks, J. D., Wei, W., Pollack, J. R., West, R. B., Shin, J. H., Sunwoo, J. B., … Fazli, L. (2016). Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 76(15), 1409–19.
-
Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches.
Uppaluri, R., Bell, R. B., & Sunwoo, J. B. (2016). Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. Oral Oncology, 58, 49–51.
-
Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan, K., Holsinger, C., Dosiou, C., Sunwoo, J. B., Akatsu, H., Haile, R., & Gevaert, O. (2016). Development of prognostic signatures for intermediate-risk papillary thyroid cancer. BMC Cancer, 16(1), 736-?
-
Flexible radioluminescence imaging for FDG-guided surgery
King, M. T., Jenkins, C. H., Sun, C., Carpenter, C. M., Ma, X., Cheng, K., … Xing, L. (2016). Flexible radioluminescence imaging for FDG-guided surgery. MEDICAL PHYSICS, 43(10).
-
Transcription factor Dlx3 induces aryl hydrocarbon receptor promoter activity.
Shin, J. H., Haggadone, M. D., & Sunwoo, J. B. (2016). Transcription factor Dlx3 induces aryl hydrocarbon receptor promoter activity. Biochemistry and Biophysics Reports, 7, 353–60.
-
The aryl hydrocarbon receptor is required for the maintenance of liver-resident natural killer cells.
Zhang, L. H., Shin, J. H., Haggadone, M. D., & Sunwoo, J. B. (2016). The aryl hydrocarbon receptor is required for the maintenance of liver-resident natural killer cells. Journal of Experimental Medicine, 213(11), 2249–57.
-
Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor.
Kim, J., Ho Shin, J., Chen, C.-H., Cruz, L., Farnebo, L., Yang, J., … Sunwoo, J. B. (2017). Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor. Oncotarget.
-
Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype.
Brennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017). Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype. EBioMedicine, 17, 223–36.
-
Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., … Divi, V. (2017). Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head & Neck.
-
ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma
Chen, C., Shin, J. H., Eggold, J. T., Chung, M. K., Zhang, L. H., Lee, J., & Sunwoo, J. B. (2016). ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma. ONCOTARGET, 7(43), 70738–49.
-
Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., … Kohrt, H. E. (2017). Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. ANNALS OF ONCOLOGY, 28(2), 415–20.
-
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017). NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. Scientific Reports, 7(1), 17064.
-
CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug.
Chung, M. K., Jung, Y. H., Lee, J. K., Cho, S. Y., Murillo-Sauca, O. J., Uppaluri, R., … Sunwoo, J. B. (2017). CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
-
The aryl hydrocarbon receptor modulates the function of human CD56bright NK cells.
Moreno-Nieves, U. Y., Mundy, D. C., Shin, J. H., Tam, K., & Sunwoo, J. B. (2018). The aryl hydrocarbon receptor modulates the function of human CD56bright NK cells. European Journal of Immunology.
-
Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam, K., Schoppy, D. W., Shin, J. H., Tay, J. K., Moreno-Nieves, U., Mundy, D. C., & Sunwoo, J. B. (2018). Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 194599818756627.
-
-
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., … Divi, A. V. (2018). PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 194599818788057.
-
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Sep 2019
Dr. Sunwoo has an outstanding bedside manner, very inclusive, valued my input, provided options he was genuine, caring, empathetic, & compassionate about his work, I felt very confident about his work to care for me & treatment.
SHC Patient, Mar 2019
I can't say enough about the thoughtful, intelligent and warm care I received!
SHC Patient, Mar 2019
Great doctor. Good experience.
SHC Patient, Sep 2018
Great professional, eminence offered much love & tranquil spirit.
SHC Patient, Sep 2018
Dr. Sunwoo & staff are excellent!
SHC Patient, Aug 2018
Good experience. Dr. very good.
SHC Patient, Aug 2018
Dr. Sunwoo is an excellent doctor who had great patience and is very meticulous and thorough.
SHC Patient, Jun 2018
Before having referred to Stanford for thyroid cancer, I had many tests & providers in my local area. At Stanford I saw true competence & professionalism for the first time. Wish I lived closer so I could have all my medical needs taken care of there.
SHC Patient, May 2018
Good experience.
SHC Patient, May 2018
I have been most satisfied with Dr. John Sunwoo. He is very thorough and explains procedures very well. He is a true asset to Stanford Health Care.
SHC Patient, Jan 2018
Dr. Sunwoo has been my follow up physician since Dr. Fe retired. I have complete confidence in him.
SHC Patient, Jan 2018
The doctor (Dr. Sunwoo) was very clear in explaining what will happen & what will be done to the patient.
SHC Patient, Jan 2018
I do recommend. May God bless the dr.
SHC Patient, Oct 2017
Excellent...
SHC Patient, Sep 2017
Excellent.
SHC Patient, Aug 2017
Everyone - From arrival to MD - Terrific!
SHC Patient, May 2017
Explained what was going to happen and I could understand what was being said.
SHC Patient, May 2017
I recommend Stanford to anyone I know regularly.
SHC Patient, May 2017
The medical staff was the most informed and, all around, professional I have ever met.
SHC Patient, Apr 2017
Dr. explain the problem clearly.
SHC Patient, Apr 2017
Dr. Sunwoo is very caring genuine physician.
SHC Patient, Mar 2017
Very inspiring and hopeful thank you.
SHC Patient, Mar 2017
Dr. Sunwoo made a very scary experience easy. He is the best!
SHC Patient, Mar 2017
All who cared for me were excellent.
SHC Patient, Jan 2017
Doctor Sunwood went out of his way to see me and accommodate my schedule in treatment.
SHC Patient, Nov 2016
Dr. Sunwoo & staff are outstanding.
SHC Patient, Sep 2016
Dr. John Sunwoo is very friendly, his explanation about my problem were easy to understand. I have complete confidence in Dr. Sunwoo. I would recommend him to others. Zoya Benjamin, PA, also does a great job.
SHC Patient, Aug 2016
If this staff is any example of the rest of the hospital we wish we lived closer to have the best of our needs cared for.
SHC Patient, May 2016
A great doctor.
SHC Patient, Apr 2016
Thanks to Dr. Sunwood John Bing, great skills and professional, and nice like an angel!
SHC Patient, Apr 2016
Super.
SHC Patient, Mar 2016
I recommend it because they took very good care of me.
SHC Patient, Feb 2016
Dr. Sunwoo and my whole team are wonderful!! Love them!
SHC Patient, Jan 2016
Excellent!
SHC Patient, Dec 2015
As always, Dr. Sunwood and staff were great!!
SHC Patient, Nov 2015
I have given Dr. Sunwoo 5's in every area. He is beyond "very good"; he is outstanding as a care provider.
SHC Patient, Oct 2015
Wish that doctor himself had come to see me and answer my questions before I was discharged from the hospital.
SHC Patient, Sep 2015
Dr. Sunwoo never seems to be in a hurry. He is a great dr. and does beautiful work.
SHC Patient, Aug 2015
Could not ask for more.
SHC Patient, Jun 2015
I'm very pleased.
SHC Patient, May 2015
My care under Dr. Sunwoo has been excellent.
SHC Patient, Mar 2015
Good.
SHC Patient, Dec 2014
Very concerned about follow-on care.
SHC Patient, Nov 2014
Dr. Sunwoo is an all around FABULOUS dr.!
SHC Patient, Sep 2014
The PA took so much time with us and spoke so well of the doctor. PA also shared some info and encouragement that the doctor eventually shared.
SHC Patient, Aug 2014
Dr. Sunwoo was kind & positive about a scary medical condition one of the best drs. I've ever been to.
SHC Patient, Mar 2014
Care provided was excellent! Thank you.
SHC Patient, Mar 2014
I was very impressed with Dr. Sunwoo. He was so clear in his explanation of my health care & problem.
SHC Patient, Jan 2014
Long drive and limited available scheduling.
SHC Patient, Sep 2019
Dr. Sunwoo has an outstanding bedside manner, very inclusive, valued my input, provided options he was genuine, caring, empathetic, & compassionate about his work, I felt very confident about his work to care for me & treatment.
SHC Patient, Mar 2019
I can't say enough about the thoughtful, intelligent and warm care I received!
SHC Patient, Mar 2019
Great doctor. Good experience.
SHC Patient, Sep 2018
Great professional, eminence offered much love & tranquil spirit.
SHC Patient, Sep 2018
Dr. Sunwoo & staff are excellent!
SHC Patient, Aug 2018
Good experience. Dr. very good.
SHC Patient, Aug 2018
Dr. Sunwoo is an excellent doctor who had great patience and is very meticulous and thorough.
SHC Patient, Jun 2018
Before having referred to Stanford for thyroid cancer, I had many tests & providers in my local area. At Stanford I saw true competence & professionalism for the first time. Wish I lived closer so I could have all my medical needs taken care of there.
SHC Patient, May 2018
Good experience.
SHC Patient, May 2018
I have been most satisfied with Dr. John Sunwoo. He is very thorough and explains procedures very well. He is a true asset to Stanford Health Care.
SHC Patient, Jan 2018
Dr. Sunwoo has been my follow up physician since Dr. Fe retired. I have complete confidence in him.
SHC Patient, Jan 2018
The doctor (Dr. Sunwoo) was very clear in explaining what will happen & what will be done to the patient.
View All 49 Patient Comments »